Refaei Belal Ibrahim on Muck Rack

Refaei Belal Ibrahim

As seen in: Wiley Online Library, eCancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Refaei Belal

Contact Refaei Belal, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Loncastuximab Tesirine in a Frail, Heavily Pretreated Patient With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Case Report

|
By Reyad Dada, Refaei Belal Ibrahim
| Wiley Online Library Verified
ADC antibody–drug conjugate CAR Chimeric antigen receptor CBC Complete blood count CR Complete response CT Computed tomography DLBCL Diffuse large B-cell lymphoma DOR Duration of response ECOG Eastern Cooperative Oncology Group GEMOX Gemcitabine and oxaliplatin LDH Lactate dehydrogenase miniR-CHOP Rituximab, cyclophosphamide and prednisone doxorubicin, with vincristine omitted due to polyneuropathy ORR Overall response rate OS Overall survival PFS Progression-free survival R/R DLBCL...
Open in Who Shared Issue with article?

Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with

|
By Jamal Zekri, Mohammed Abbas Baghdadi, Refaei Belal Ibrahim, Abdelrazak Meliti
| eCancer Verified
How likely is this article to improve patient care in your region? Is reading this article likely to improve your clinical practice? How likely are you to recommend this article to a colleague?
Open in Who Shared Issue with article?

Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with

|
By Jamal Zekri, Mohammed Abbas Baghdadi, Refaei Belal Ibrahim, Abdelrazak Meliti
| eCancer Verified
Category Sub-category Article type Volume Abstract | Full Article | PDF Research Background: Oral capecitabine in combination with intravenous oxaliplatin (XELOX) or irinotecan (XELIRI) are acceptable substitutions to fully intravenous regimens. Biweekly (as opposed to weekly) cetuximab is more convenient when combined with biweekly chemotherapy.
Open in Who Shared Issue with article?
See all 3 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified